ctDNA Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ NSCLC in the MDT Diagnostic Model
Status:
Not yet recruiting
Trial end date:
2024-08-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, open phase II clinical study, in patients with unresectable stage III
non-small cell lung cancer,to evaluate the effectiveness and safety of Almonertinib induction
therapy, and ,to evaluate the effectiveness and safety of different treatment decisions
guided by ctDNA dynamic monitoring after local treatments (surgical or radical radiotherapy)
evaluated by MDT.
The study includes a screening period (not more than 28 days after the subject signs informed
consent to before the first medication), treatment period (including induction\MDT+topical
therapy\adjuvant or consolidation therapy) and follow-up period (including safety and
survival) .